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We previously reported that stable transfection of protein kinase C alpha (PKCa) into T47D human breast cancer cells results in
tamoxifen (TAM)-resistant tumour growth. Relevance of PKCa expression in clinical specimens was determined by comparing PKCa
expression in tumours from patients exhibiting disease recurrence with patients remaining disease-free following TAM treatment.
Our results suggest that PKCa expression may predict TAM treatment failure.
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Resistance to tamoxifen (TAM), the endocrine treatment of choice
for all stages of breast cancer, represents a significant clinical
problem in the management of the disease. Identification of
the key factors involved in the molecular mechanism of TAM
resistance will undoubtedly lead to the development of logical
therapeutic targets. It is well documented that the oestrogen
receptor (ER) and protein kinase C (PKC) activity and abundance
are inversely related in breast cancer cell lines and that PKC is
elevated in malignant but not normal breast tissue (Borner et al,
1987; O’Brian et al, 1989; Gordge et al, 1996). Furthermore,
increased activator protein-1 (AP-1) activity occurs in hormone-
independent breast cancer cell lines and tumours (Dumont et al,
1996; Johnston et al, 1999; Schiff et al, 2000). Protein kinase C is an
upstream activator of the AP-1 pathway. We reported that stable
transfection of PKCa into T47D human breast cancer cells results
in a hormone-independent phenotype and TAM-resistant tumour
growth (Tonetti et al, 2000). Tumours formed from these cells
grow in the presence of TAM and regress upon 17b-oestradiol
(E2) administration (Chisamore et al, 2001). Our finding that
both E2 and the pure antioestrogen, ICI 182,780, can inhibit these
TAM-resistant tumours may now allow us to predict the efficacy
of endocrine therapy. For example, tumours overexpressing
PKCa may be stimulated to grow if the patient is treated with
TAM, and therefore a more appropriate therapy may be an
oestrogen-like compound or a pure antioestrogen. However, our
T47D/PKCa tumour model cannot determine whether PKCa
overexpression occurs in patients prior to TAM exposure, or
is a result of long-term TAM treatment. To address this question,
we identified paired paraffin-embedded tumour blocks from
patients with primary and recurrent tumour samples that
were available from the database of the Lynn Sage Breast Center
of Northwestern Memorial Hospital. In addition, primary biopsies
from patients remaining disease-free with at least 5 years of follow-
up were identified. To determine changes, if any, in the intensity
and/or incidence of PKCa expression, immunohistochemistry was
performed on all biopsies.
MATERIALS AND METHODS
Tumour specimens
Paired paraffin-embedded tumour blocks from 15 patients where
primary and recurrent tumour samples were identified from the
database of the Lynn Sage Breast Center of Northwestern Memorial
Hospital. In addition, 15 primary biopsies from patients remaining
disease-free with at least 5 years of follow-up were identified. This
study was approved by the Institutional Review Board at North-
western University Medical School.
Immunohistochemistry
Sections, 4mm thick, were deparaffinised with 100% CitriSolv
dipped in 100% ethanol. Endogenous peroxidase activity was
blocked with 0.3% H2O2 in methanol for 30min, followed
by immersion in graded alcohols. After rinsing in distilled water,
antigen retrieval was accomplished by boiling in citrate buffer.
After rinsing with PBS, the sections were blocked for 1h
with normal goat serum. The sections were incubated overnight
at 4
oC with a PKCa primary polyclonal antibody (C-20, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). The sections were
incubated for 30min with biotinylated goat anti-rabbit IgG
(HþL), followed by incubation for 30min with HRP–Streptavidin
(HistoMark Biotin Streptavidin kit; KPL, Gaithersburg, MD,
USA). Sections were rinsed with PBS for 5min between each
reaction. 3,30-Diaminobenzidine (DABþ) solution (DAKO, Car-
pinteria, CA, USA) was used as a chromogen. Finally, sections were
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ycounterstained with haematoxylin. Stained sections were photo-
graphed at  40 magnification using an Olympus BX40 micro-
scope attached to a SONY DP10 digital camera. Analysis of the
entire slide was performed to score the intensity of staining.
Intensity was evaluated semiquantitatively by assigning the score
of either negative (0), weak positive (1þ, o10% staining),
moderate (2þ, 10–30% staining), or intense (3þ, 430%
staining). The specificity of the staining was ascertained by several
methods, including the use of PBS or isotypic nonspecific
antibodies in lieu of the specific anti-PKC-a antibody. Dilution
experiments using the primary antibody to assess specificity and
observe extinction of signal were also performed. In addition,
staining with the PKCa antibody was repeated in the presence of a
specific PKCa blocking peptide (sc-3007, Santa Cruz, USA). There
was no staining of the breast epithelial cells under these
conditions.
RESULTS
To determine the possible association of PKCa overexpression
with the acquisition of TAM resistance, PKCa expression was
assessed by immunohistochemical staining in two patient popula-
tions treated with TAM: patients remaining disease-free following
TAM treatment and patients exhibiting disease recurrence.
Representative immunohistochemical staining of patient tumours
demonstrates the cytoplasmic localisation of PKCa (Figure 1).
Seven percent (one out of 15) of patients remaining disease-free
exhibited moderate PKCa staining and the remaining 14 biopsies
exhibited negative or weak positive PKCa immunostaining
(Table 1). Seventy-three percent (11 out of 15) of patients
exhibiting disease recurrence showed moderate to intense PKCa
immunoreactivity in both the primary and recurrent tumour
(Table 2). These results suggest that PKCa overexpression is more
frequent in primary tumours of patients who experience disease
recurrence compared with patients who remain disease-free.
Furthermore, PKCa overexpression may be predictive of TAM
treatment failure, since expression is high in the primary biopsy
and does not increase in the second biopsy following TAM
exposure. However, the sample size of this study is small, and the
majority of patients who relapse are younger (mean age 44 years)
Figure 1 Protein kinase C alpha immunohistochemical staining of
representative patient tumours. (A, B) Matched primary and recurrent
biopsies from patient #10. (C) Primary biopsy from patient #4 exhibiting
no disease recurrence. Magnification  40.
Table 1 PKCa immunostaining: patients remaining disease-free
Patient no. Age (y) LN
a+/total Grade Primary biopsy
b
1 87 10/19 2 1+
2 41 20/21 3 1+
3 51 0/13 1 0
4 45 0/18 2 0
5 54 0/0 1 0
6 46 7/18 3 0
7 40 0/18 2 0
8 35 0/0 2 0
9 53 0/0 2 0
10 69 0/0 2 1+
11 58 0/0 3 0
12 48 8/20 2 0
13 50 20/21 3 0
14 72 0/0 1 2+
15 56 0/24 3 1+
PKCa¼protein kinase C alpha.
aLN¼lymph node;
b0¼negative; 1+¼o10%
staining; 2+¼10–30% staining; 3+¼430% staining.
Table 2 PKCa immunostaining: patients exhibiting recurrence
Patient
no.
Age at
diagnosis (y) LN
a+/total Grade
Primary
biopsy
b
Recurrent
biopsy
b
1 45 0/28 3 0 0
2 36 17/17 3 0 1+
3 49 0/0 3 0 1+
4 36 0/13 3 0 1+
5 40 20/24 3 3+ 2+
6 48 0/18 3 3+ 2+
7 42 0/11 2 3+ 3+
8 60 8/16 3 3+ 3+
9 37 0/15 3 2+ 2+
10 41 2/14 3 3+ 3+
11 54 0/0 2 2+ 2+
12 56 18/26 3 2+ 2+
13 44 0/0 2 2+ 2+
14 46 4/8 3 2+ 2+
15 30 2/9 3 2+ 1+
PKCa¼protein kinase C alpha.
aLN¼lymph node;
b0¼negative; 1+¼o10%
staining; 2+¼10–30% staining; 3+¼430% staining.
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patients (mean age 54 years).
DISCUSSION
The implications for the use of PKCa overexpression as a
predictive tool for improved therapeutic options are based on
our T47D/PKCa xenograft model system demonstrating that E2
induces tumour regression (Chisamore et al, 2001). Other
examples of E2-induced regression in both tumours and breast
cancer cell lines have been described. Similar to the T47D/PKCa
tumour, the T61 tumour derived from a primary breast cancer
(Brunner et al, 1996) is ovarian-independent and E2 is inhibitory.
However, in contrast to the T47D/PKCa tumour, growth of T61 is
inhibited by TAM. A cyclical model of hormonal response in MCF-
7 tumours has been described wherein after 1 year of TAM
treatment, tumours are stimulated by both E2 and TAM, but
following 5 years of treatment, E2 causes tumour regression (Yao
et al, 2000). We have reported that PKCa is overexpressed in MCF-
7 tumours after different periods of exposures to TAM (1 year and
5 years) (Chisamore et al, 2001). Both the MCF-7-derived E8CASS
cell variant (Sonnenschein et al, 1994) and the MCF-7 long-term
oestrogen deprived (LTED) cells (Masamura et al, 1995; Shim et al,
2000) were derived by long-term oestrogen deprivation and
undergo apoptosis in response to E2 (Song et al, 2000). A recent
report demonstrated that E2-induced apoptosis is likely triggered
via a Fas-mediated mechanism (Song et al, 2001). T47D L(hE) cells
described by Fernandez et al (1998) were cultured in E2-deficient
media long term and also exhibit E2-induced growth inhibition.
However, these cells were found to express elevated ER levels with
aC -A transversion resulting in an H513N amino-acid change in
the ligand-binding domain.
These findings, taken together with our previous observation
that E2 has a novel antitumour effect on T47D/PKCa breast
tumours (Chisamore et al, 2001), may have important therapeutic
implications in the management of breast cancer patients. Elevated
tumour expression of PKCa may predict TAM treatment failure
and indicate that an oestrogenic compound may be more
efficacious than TAM and perhaps an aromatase inhibitor. A
recent updated analysis of diethylstilbestrol (DES) vs TAM for the
treatment of postmenopausal metastatic breast cancer indicates
that there is survival advantage for women on DES compared to
women on TAM (Peethambaram et al, 1999); however, the basis of
this survival advantage remains unknown. Perhaps, preselection of
a subset of patients who overexpress PKCa may improve upon the
outcome of treatment with DES. We are in the process of
expanding these studies in a larger population of patients who
are matched by age and stage to substantiate these preliminary
findings. Examination of a larger patient series will also allow us to
address the relations between ER status and PKCa expression as
well as between the intensity of PKCa staining and time to disease
recurrence.
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